



June 1, 2024

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. (“Teva”) submits this information pursuant to 18 V.S.A. § 4637(b). On May 13, 2023, Teva released the following generic prescription drug to the commercial market:

NDC	Product Description	WAC
68546-0473-56	AUSTEDO XR® 30mg (30ct)	\$9,761.90
68546-0474-56	AUSTEDO XR® 36mg (30ct)	\$12,202.40
68546-0475-56	AUSTEDO XR® 42mg (30ct)	\$14,642.90
68546-0476-56	AUSTEDO XR® 48mg (30ct)	\$14,642.80

Teva now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

1. US and international marketing and pricing plans used at launch: Teva declines to provide this information in accordance with 18 V.S.A. § 4637(d).
2. Estimated volume of patients Research suggests that the diagnosed prevalence for Huntington's is about 33,000. Tardive dyskinesia affects about 500,000 individuals in the United States
3. Whether the FDA granted breakthrough therapy designation or priority review: No.
4. Date and price of acquisition: Not applicable; Teva developed the product.

* * * *

Teva provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this report, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Thank you for your consideration.
Sincerely,

Priti Patel
Senior Manager, Pricing & Contracting